Orchestra BioMed (OBIO) Q3 2026 earnings review
Orchestra BioMed's pacemaker trial is full, but its spending climbs
Orchestra BioMed, a developer of heart devices, filled its main pacemaker trial while the cost of its trials kept climbing. Chief executive David Hochman said the pacemaker treatment is nearing its main results. One-off gains made the loss look smaller; excluding them, by our math, it rose 24% from a year ago. A share sale after the quarter added $81 million; with existing cash, the company said, that funds it through 2028.
| Loss excluding one-off gains | $25.8M $20.8M a year ago |
|---|---|
| Research spending | $17.7M +26% from a year ago |
| Cash and investments | $101.9M $106.5M in December |
| Funding outlook | Through 2028 after the November share sale |
⚖️ Verdict: 🟢 Bullish
The story got better because the trial is full and the company holds the cash to reach its results. One caution: by our math, cash spending increased 34% from a year ago, and royalty and loan deals claim part of future pacemaker income.
The question now is whether the pacemaker treatment lowers blood pressure enough to win approval. If it does, Medtronic plans to file promptly; if not, Orchestra BioMed must depend on a balloon program still enrolling patients. Results due in May 2027 will settle it.
🐂 Bull Case
Pacemaker Trial Finished Enrolling Above Its Target
AVIM Therapy is software that runs on a standard pacemaker, and Orchestra BioMed designed it to lower blood pressure. Medtronic, the pacemaker leader, holds the worldwide rights to sell it once approved. Chief executive David Hochman said AVIM is "nearing pivotal primary endpoint results", meaning the main measures of its final large trial.
Orchestra BioMed has now enrolled 349 patients at 92 sites in BACKBEAT, that final trial. The total "exceeded enrollment target", the device developer said, and about half of the patients came from the US. The FDA also confirmed in writing that Medtronic can file a supplement, an add-on to an approval that already exists.
This matters because Hochman's claim now comes with a date. Every patient must finish three months of follow-up, and the partners then plan to submit the results for presentation next May. The company said Medtronic plans to file "promptly following presentation of the primary endpoint results", assuming they are positive.
What to watch: the primary results at the Heart Rhythm Society meeting next May. A clear fall in blood pressure for AVIM patients, compared with the control group, would trigger Medtronic's US filing.
Fresh Cash Covers Both Trials Through 2028
Orchestra BioMed earns almost nothing from sales, so outside money pays for its late-stage trials. A share sale that closed on November 9 raised $80.5 million after fees. Chief executive David Hochman said that money and the quarter-end cash "provide funding through 2028".
This matters because both key results should arrive before the money runs out. BACKBEAT, the pacemaker trial, reports next May, and the Virtue balloon trial aims to finish enrolling by the end of 2027. But Orchestra BioMed must start repaying a $15 million Hercules Capital loan in 2028. That loan's minimum-cash rule can apply as early as 2027.
What to watch: cash spending in each 2027 quarterly report. If it keeps rising at this year's pace, the November money may not last until the end of 2028.
Enrollment Speeds Up in the Virtue Balloon Trial
Virtue SAB is a balloon that infuses the drug sirolimus as a liquid into the wall of a narrowed artery. Chief executive David Hochman said the device works "without the need for a fragile balloon coating", which sets it apart from rival balloons.
Its US trial compares the device with Boston Scientific's AGENT, a coated balloon on sale today, in arteries that narrow again inside a stent. The company called enrollment "accelerating". In SABRE, a small European pilot study, the treated artery failed in 14.3% of patients after three years.
But Orchestra BioMed gave no patient count, so readers cannot test that claim yet. Terumo, its former partner, left the program last year, and the device developer now pays for the trial alone.
What to watch: a first patient count for the Virtue Trial in the next quarterly report. Steady growth toward the full-enrollment goal would keep the trial on schedule.
🐻 Bear Case
Trial Costs Push the Underlying Loss Up 24%
Orchestra BioMed said its loss for common shareholders shrank 6% from a year ago. One-off gains explain the drop, led by a $6.1 million milestone from the sale of Vivasure, a device company it had invested in. Without those gains, by our math, the loss rose 24%.
Research spending grew 26%, mostly for BACKBEAT, the pacemaker trial, and the Virtue balloon trial, Orchestra BioMed said. Clinical trial costs climbed 52%, and staff and consultant costs increased 35%. Overhead fell 21%, mostly on lower legal and professional fees.
- Cash spent on operations and equipment: $19.9 million, against $14.9 million a year ago
- Research share of total costs: 76%, against 66%
- Loss per share without the Vivasure gain: $0.40, level with a year ago by our math
Chief executive David Hochman said the company is in a strong position "to deliver key value-creating milestones". But cash spending rose by a third while revenue almost disappeared, so each quarter now uses more of the new money.
What to watch: cash spending in the fourth-quarter report early next year. Another rise of this size would cut how long the November cash lasts.
Royalty Deals and Loans Raise Borrowing Costs
Orchestra BioMed also funds its trials by selling claims on future income. Ligand Pharmaceuticals paid $35 million for a share of revenue from AVIM, the blood-pressure pacemaker software, and Virtue, the drug balloon. Medtronic lent $20 million on a note that converts into a revenue share if AVIM wins approval.
Net interest expense rose to $2.5 million from $0.5 million a year ago. The filing puts Ligand's effective interest rate at 21.3% a year, but most of that interest needs no cash today. Instead, future product income will pay it, because Ligand takes 17% of product revenue up to a yearly cap.
What to watch: the Ligand balance, now $36.8 million, in the annual report due in March. A steady climb would hand lenders more of the first AVIM income.
👓 Other Themes
Revenue Fell Because the Terumo Deal Ended
Total revenue fell 89% from a year ago because partnership income disappeared. That income came from Terumo, which had partnered on Virtue SAB, the drug-infusing balloon. Terumo ended the deal in October 2025 and bought $20 million of preferred shares instead. What remains is small sales of FreeHold organ retractors, tools for keyhole and robotic surgery.
💲 Other KPIs
The share count kept climbing as Orchestra BioMed sold stock through its at-the-market program, which sells shares gradually on the exchange. By our math, quarter-end shares grew about 2.5% a quarter this year. The November share sale adds 17.25 million more, a 28% jump.
Stockholders' equity, the accounting value of the owners' stake, shrank to $7.8 million from $53.6 million in December. Losses used up most of it, while much of this year's new money came through royalty and loan deals that count as liabilities. The November share sale will rebuild it.
Sales of FreeHold organ retractors, tools for keyhole and robotic surgery, dropped 35% from a year ago. The device developer said customers bought fewer units at unchanged prices. These are its only product sales, and they cover a tiny share of its costs.
Stock-based pay, the cost of shares and options granted to staff, came in 24% below a year ago. It has stayed under the 2025 level for three straight quarters. The lower charge held down overhead even as Orchestra BioMed hired for its trials.
🔮 Guidance
New. Orchestra BioMed says its cash pays for operations through 2028. By our math, the $101.9 million at quarter-end plus the November proceeds come to about $182 million. That lasts about nine quarters at the third quarter's spending pace, which reaches the end of 2028. Faster spending would shorten that time.
New. The device developer and Medtronic plan to submit the pacemaker trial's main results to the Heart Rhythm Society meeting in May 2027. First, every patient must finish three months of follow-up, and the partners must lock the trial database. Medtronic then plans its US filing for AVIM, the blood-pressure pacemaker software, if the results are positive.
New. The plan has the Virtue balloon trial fully enrolled by the end of 2027. The company has not said how many patients have joined so far, so readers cannot check progress against the target. Its quarterly filing warns that it cannot promise that timing.
❓ Key Questions
How many patients has the Virtue Trial enrolled?
The company described Virtue enrollment as "accelerating" but gave no count. A number set against the 740-patient goal would show whether full enrollment by the end of 2027 is realistic.
What blood pressure drop counts as BACKBEAT success?
Neither the release nor the filing states how large a drop the main measure must show. Readers need that threshold before May to judge the results, because Medtronic plans to file only if they are positive.
How much will cash spending rise in 2027?
Cash spending rose by a third this quarter. The claim of funding through 2028 depends on that pace, and Virtue Trial costs could climb as more hospitals join.
Will the company meet the Hercules minimum-cash rule?
The Hercules loan requires a cash balance tied to the amount borrowed, starting as early as January 2027. A breach would count as a default under the loan, so the company should say how much room it has.
Will Medtronic build AVIM into its leadless pacemaker?
A 2025 amendment set out a plan for AVIM in Medtronic's leadless pacemaker, a device with no wires, with Orchestra BioMed paying some costs up to a cap. The filing does not say whether Medtronic will proceed.